Eisai Inc - Company Profile
Powered by 
All the data and insights you need on Eisai Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Eisai Inc Strategy Report
- Understand Eisai Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Eisai Inc (Eisai America), a subsidiary of Eisai Co Ltd, is a healthcare company that discovers, develops, and markets pharmaceutical products. The company's major products include Aricept for Alzheimer’s treatment, Banzel for adjunctive treatment, and Dayvigo for the insomnia. The company’s research and development activities focus on therapeutic areas such as neuroscience; cancer, antibody-based programs; vascular, inflammatory, and immunological reaction. Eisai America established partnerships and collaborations with global companies such as Pfizer, Janssen Pharmaceutica Inc, Elan Pharma International Ltd, and Elan Pharmaceutical Inc for the development and distribution of drugs. Eisai America is headquartered in New Jersey, the US.
Headquarters
United States of America
Address
200 Metro Blvd, Nutley, New Jersey, 07110
Website
us.eisai.com
Telephone
1 201 6921100
Industry
Pharmaceuticals and Healthcare
Eisai Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Aricept |
| Banzel |
| Halaven |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Plans/Strategy | In March, the company announced its plans to invest up to US$15 million in C2N Diagnostics LLC. |
| 2023 | Regulatory Approval | In July, the company received FDA approval for Leqembi for the treatment of Alzheimer's disease. |
| 2022 | Contracts/Agreements | In December, the company and Washington University School of Medicine entered into a research collaboration agreement to create potential novel treatments for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease. |
Competitor Comparison
| Key Parameters | Eisai Inc | Koronis Pharmaceuticals, Inc. | Adlyfe Inc | Ceregene Inc | CerFlux Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Nutley | Redmond | Rockville | San Diego | Birmingham |
| State/Province | New Jersey | - | Maryland | California | Alabama |
| No. of Employees | - | 12 | - | - | - |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tatsuyuki Yasuno | Chairman; Chief Executive Officer | Executive Board | - | - |
| Lynn Kramer, M.D. | Chief Clinical Officer ADBH | Senior Management | - | - |
| Takashi Owa | Chief Discovery Officer; President - Deep Human Biology Learning | Senior Management | - | - |
| Masahito Suzuki | Vice President; Chief Financial Officer | Senior Management | 2022 | - |
| Vincent Andrews | General Counsel; Chief Compliance Officer; Secretary; Senior Vice President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward